What is the safest pharmacotherapy option for a 65-year-old female patient with stable Cardiovascular Disease (CVD) and hypertension to quit smoking?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 2, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Safety of Smoking Cessation Pharmacotherapy in Patients with Cardiovascular Disease

Based on the CATS trial by Benowitz and colleagues, no differences were seen with varenicline, bupropion SR, and nicotine patches in terms of time to CV event, blood pressure, or heart rate in patients with cardiovascular disease.

Efficacy and Safety of Smoking Cessation Pharmacotherapies in CVD Patients

Evidence from the CATS Trial

The CATS trial specifically evaluated the cardiovascular safety of smoking cessation pharmacotherapies in patients with cardiovascular disease, finding no significant differences between varenicline, bupropion SR, and nicotine patches regarding:

  • Time to cardiovascular events
  • Blood pressure changes
  • Heart rate changes

Safety of Nicotine Replacement Therapy (NRT)

  • Nicotine patches have been extensively studied in patients with stable cardiovascular disease and have been shown to be safe 1
  • Clinical trials have demonstrated that NRT does not cause aggravation of myocardial ischemia or arrhythmia in coronary patients 2
  • NRT appears safe in patients with cardiovascular disease, with no evidence of increased risk of cardiac events 3

Safety of Varenicline

  • Varenicline has been evaluated in randomized, double-blind, placebo-controlled trials in smokers with stable cardiovascular disease 4
  • In the FDA label, varenicline was found to be well-tolerated in patients with cardiovascular disease, with no significant increase in cardiovascular mortality compared to placebo (0.3% vs 0.6%) 4
  • While early concerns existed about potential cardiovascular events, current evidence neither definitively supports nor refutes such an association 5

Safety of Bupropion SR

  • Bupropion SR has relatively few cardiovascular adverse effects and may be useful for patients with CVD 6
  • However, it carries risks of seizures and allergic reactions that should be monitored 3

Comparative Efficacy of Smoking Cessation Pharmacotherapies

Varenicline

  • Highest estimated abstinence rates (33.2%) compared to other smoking cessation medications 3
  • Superior efficacy with an odds ratio of 3.1 versus placebo and 1.6 versus nicotine patch therapy 3
  • Recommended dosing: 0.5 mg once daily (days 1-3), 0.5 mg twice daily (days 4-7), then 1 mg twice daily 3

Bupropion SR

  • Lower cessation rates compared to varenicline (24.2% vs 33.2%) 3
  • Standard dosing: 150 mg twice daily 3

Nicotine Replacement Therapy

  • Combination NRT (patch + short-acting form) is more effective than single NRT products 3
  • Standard dosing for nicotine patch: 21mg/24hr patch for the first 6 weeks 3

Clinical Approach for the 65-year-old Female Patient with CVD

Assessment

  • Evaluate the stability of her cardiovascular disease
  • Review current medications for potential interactions
  • Assess level of nicotine dependence

Recommendations

  1. All three pharmacotherapies (varenicline, bupropion SR, and nicotine patches) can be safely used in patients with stable cardiovascular disease based on the CATS trial findings
  2. For optimal efficacy, varenicline would be the preferred option given its superior quit rates 3
  3. Combine pharmacotherapy with behavioral counseling for best results 3
  4. Schedule follow-up within 2-3 weeks to assess medication usage, side effects, and smoking status 3

Monitoring Considerations

  • Monitor blood pressure and heart rate at follow-up visits
  • Be alert for any cardiovascular symptoms
  • Ensure adequate duration of treatment (typically 12 weeks)
  • Continue periodic follow-up at 12-week intervals 3

Benefits of Smoking Cessation in CVD Patients

Quitting smoking provides substantial benefits for patients with cardiovascular disease:

  • Reduces overall mortality by 25% to 50% in those who have suffered an MI 1
  • At least 50% of this decline is seen in the first year 1
  • Reduces risk of recurrent cardiovascular disease by approximately one-third 7
  • Advanced age does not attenuate the benefits of quitting 1

The benefits of smoking cessation far outweigh any potential risks associated with pharmacotherapy in patients with stable cardiovascular disease.

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

3
Guideline

Smoking Cessation Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

5
Research

Nicotine receptor partial agonists for smoking cessation.

The Cochrane database of systematic reviews, 2016

6
Research

Smoking cessation for patients with cardiovascular disease: what is the best approach?

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2003

7
Research

Smoking cessation for secondary prevention of cardiovascular disease.

The Cochrane database of systematic reviews, 2022

Related Questions

Is it safe to use nicotine patches (nicotine replacement therapy) in patients on Depo-Provera (medroxyprogesterone acetate)?
What is the recommended first-line treatment for smoking cessation in a patient with stable Cardiovascular Disease (CVD), diabetes, and hypertension, who has previously tried Nicotine Replacement Therapy (NRT)?
What is the best recommendation for a smoking cessation treatment in a patient with a history of smoking, hypertension, and seizures?
What can help reduce the risk for cardiovascular disease in a patient who smokes and has elevated Low-Density Lipoprotein (LDL) levels?
What is the best approach for a 45-year-old male with a recent Cerebrovascular Accident (CVA) and Transient Ischemic Attack (TIA) to quit smoking?
What is the recommended first-line treatment for smoking cessation in a patient with stable Cardiovascular Disease (CVD), diabetes, and hypertension, who has previously tried Nicotine Replacement Therapy (NRT)?
What is the optimal time to recheck lipids after starting statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor) therapy?
What is the treatment for subacute bacterial endocarditis?
What is the recommended varenicline (Chantix) regimen for a 70-year-old female patient with chronic kidney disease (CKD) and impaired renal function, who smokes 1 pack per day?
What percentage of surveyed healthcare professionals reported regularly asking older patients about smoking status according to the survey done by Gautier and colleagues?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question